ABT-072

Research use only, not for human use.

ABT-072 is a novel, orally bioavailable non-nucleoside HCV NS5B polymerase inhibitor with EC50 of 0.3 nM (GT1b).

ABT-072 is a novel, orally bioavailable non-nucleoside HCV NS5B polymerase inhibitor with EC50 of 0.3 nM (GT1b); a new direct-acting antivirals (DAAs) for the treatment of HCV infection.HCV Infection Phase 2 Discontinued.

ABT-072 is a non-nucleoside NS5B polymerase inhibitor with nanomolar potency in vitro against genotype 1a and 1b hepatitis C virus polymerases.

ABT-072 (5 and/or 30 mg/kg; i.v. or p.o.) shows good PK properties.ABT-072 (2.5 and/or 30 mg/kg; i.v. or p.o.) shows low plasma clearance and high oral bioavailability. Animal Model:RatsDosage:5 and/or 30 mg/kg (Pharmacokinetic Analysis)Administration:I.v. or p.o.Result:Showed good PK properties.Animal Model:DogDosage:2.5 or 30 mg/kg (Pharmacokinetic Analysis)Administration:I.v. or p.o.Result:Showed low plasma clearance and high oral bioavailability.

ABT072

Microbiology/Virology

HCV

HCV

Infection

HCV Infection

1132936-00-5

469.556

C24H27N3O5S

>98% (HPLC)

In Vitro:?DMSO : 80 mg/mL (170.38 mM)

CS(=O)(NC1=CC=C(/C=C/C2=CC(N(C(N3)=O)C=CC3=O)=CC(C(C)(C)C)=C2OC)C=C1)=O

(E)-N-(4-(3-(tert-butyl)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2-methoxystyryl)phenyl)methanesulfonamide

(-20℃)

With Ice Pack

≥ 2 years